Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1032, Issue , 2016, Pages 79-90

  Terral, Guillaume ^a,b   Beck, Alain ^c   Cianférani, Sarah ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CNRS   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antibody drug conjugate; Antibody antigen complex; Bispecific antibody; Ion mobility mass spectrometry; Monoclonal antibody; Native mass spectrometry

Indexed keywords

CHARACTERIZATION; ION MOBILITY SPECTROMETERS; IONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MIXTURES; MONOCLONAL ANTIBODIES; PROTEINS; SPECTROMETRY;

ANTIBODY-DRUG CONJUGATES; CHROMATOGRAPHIC SEPARATIONS; DENATURING CONDITIONS; FUNCTIONAL PROPERTIES; ION MOBILITY-MASS SPECTROMETRY; MONOCLONAL ANTIBODIES (MABS); NATIVE MASS SPECTROMETRIES; PRODUCT CHARACTERIZATIONS;

ANTIBODIES;

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BISPECIFIC ANTIBODY; BRENTUXIMAB VEDOTIN; DISULFIDE; MONOCLONAL ANTIBODY; OLIGOMER; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; ION;

ANALYTIC METHOD; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COVALENT BOND; DISULFIDE BOND; DRUG CONJUGATION; DRUG DETERMINATION; HUMAN; IMMUNOGLOBULIN AGGREGATE; ION MOBILITY SPECTROMETRY; MASS SPECTROMETER; MASS SPECTROMETRY; MOLECULAR DYNAMICS; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; STOICHIOMETRY; TIME OF FLIGHT MASS SPECTROMETRY; WORKFLOW; ANIMAL; CHEMISTRY; DEVICES; EQUIPMENT DESIGN; PROCEDURES;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; EQUIPMENT DESIGN; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IONS; MASS SPECTROMETRY;

EID: 84963964134     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2016.03.044     Document Type: Article

References (90)

1. [1] Walsh, G., Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32 (2014), 992–1000.
2. [2] Elvin, J.G., Couston, R.G., van der Walle, C.F., Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int. J. Pharm. 440 (2013), 83–98.
3. [3] Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. MAbs 7 (2015), 9–14.
4. [4] Reichert, J.M., Antibody to watch in. mAbs 8 (2016), 197–204.
5. [5] Resenmann, A., Jabs, W., Wiechmann, A., Wagner-Rouset, E., Colas, O., Evers, W., Belau, E., Vorwerg, L., Evans, C., Beck, A., Suckau, D., Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing. mAbs 8 (2016), 318–330.
6. [6] Beck, A., Reichert, J.M., Antibody-drug conjugates: present and future. MAbs 6 (2014), 15–17.
7. [7] Senter, P.D., Sievers, E.L., The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30 (2012), 631–637.
8. [8] Lambert, J.M., Chari, R.V., Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J. Med. Chem. 57 (2014), 6949–6964.
9. [9] Beck, A., Haeuw, J.F., Wurch, T., Goetsch, L., Bailly, C., Corvaia, N., The next generation of antibody-drug conjugates comes of age. Discov. Med. 10 (2010), 329–339.
10. [10] Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov. Today 20 (2015), 838–847.
11. [11] Spiess, C., Zhai, Q., Carter, P.J., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67 (2015), 95–106.
12. [12] Dhimolea, E., Reichert, J.M., World Bispecific Antibody Summit September 27–28, 2011, Boston, MA. MAbs 4 (2012), 4–13.
13. [13] Fan, G., Wang, Z., Hao, M., Li, J., Bispecific antibodies and their applications. J. Hematol. Oncol., 8, 2015, 130.
14. [14] Kurbacher, C.M., Horn, O., Kurbacher, J.A., Herz, S., Kurbacher, A.T., Hildenbrand, R., Bollmann, R., Outpatient intraperitoneal catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms. Oncologist 20 (2015), 1333–1341.
15. [15] May, M.B., Glode, A., Blinatumomab: a novel bispecific, T-cell engaging antibody. Am. J. Health. Syst. Pharm. 73 (2016), e6–e13.
16. [16] Beck, A., Debaene, F., Diemer, H., Wagner-Rousset, E., Colas, O., Van Dorsselaer, A., Cianferani, S., Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J. Mass Spectrom. 50 (2015), 285–297.
17. [17] Epstein, M.S., Ehrenpreis, E.D., Kulkarni, P.M., Biosimilars: the need the challenge, the future: the FDA perspective. Am. J. Gastroenterol. 109 (2014), 1856–1859.
18. [18] Beck, A., Reichert, J.M., Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5 (2013), 621–623.
19. [19] Valliere-Douglass, J.F., Hengel, S.M., Pan, L.Y., Approaches to interchain cysteine-linked ADC characterization by mass spectrometry. Mol. Pharm. 12 (2015), 1774–1783.
20. [20] Fekete, S., Guillarme, D., Sandra, P., Sandra, K., Chromatographic electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals. Anal. Chem. 88 (2016), 480–507.
21. [21] Beck, A., Terral, G., Debaene, F., Wagner-Rousset, E., Marcoux, J., Janin-Bussat, M.C., Colas, O., Van Dorsselaer, A., Cianférani, S., Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev. Proteomics 13 (2016), 157–183.
22. [22] Beck, A., Sanglier-Cianferani, S., Van Dorsselaer, A., Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal. Chem. 84 (2012), 4637–4646.
23. [23] Katta, V., Chait, B.T., Observation of the heme globin complex in native myoglobin by electrospray-ionization mass spectrometry. J. Am. Chem. Soc. 113 (1991), 8534–8535.
24. [24] Chowdhury, S.K., Chait, B.T., Method for the electrospray ionization of highly conductive aqueous solutions. Anal. Chem. 63 (1991), 1660–1664.
25. [25] Sanglier, S., Atmanene, C., Chevreux, G., Dorsselaer, A.V., Nondenaturing mass spectrometry to study noncovalent protein/protein and protein/ligand complexes: technical aspects and application to the determination of binding stoichiometries. Methods Mol. Biol. 484 (2008), 217–243.
26. [26] Stojko, J., Fieulaine, S., Petiot-Becard, S., Van Dorsselaer, A., Meinnel, T., Giglione, C., Cianferani, S., Ion mobility coupled to native mass spectrometry as a relevant tool to investigate extremely small ligand-induced conformational changes. Analyst 140 (2015), 7234–7245.
27. [27] Nyon, M.P., Prentice, T., Day, J., Kirkpatrick, J., Sivalingam, G.N., Levy, G., Haq, I., Irving, J.A., Lomas, D.A., Christodoulou, J., Gooptu, B., Thalassinos, K., An integrative approach combining ion mobility mass spectrometry, X-ray crystallography, and nuclear magnetic resonance spectroscopy to study the conformational dynamics of alpha1—antitrypsin upon ligand binding. Protein Sci. 24 (2015), 1301–1312.
28. [28] Maple, H.J., Scheibner, O., Baumert, M., Allen, M., Taylor, R.J., Garlish, R.A., Bromirski, M., Burnley, R.J., Application of the Exactive Plus EMR for automated protein-ligand screening by non-covalent mass spectrometry. Rapid Commun. Mass Spectrom. 28 (2014), 1561–1568.
29. [29] Schmidt, C., Robinson, C.V., Dynamic protein ligand interactions–insights from MS. FEBS J. 281 (2014), 1950–1964.
30. [30] Pacholarz, K.J., Garlish, R.A., Taylor, R.J., Barran, P.E., Mass spectrometry based tools to investigate protein-ligand interactions for drug discovery. Chem. Soc. Rev. 41 (2012), 4335–4355.
31. [31] Jakobi, S., Nguyen, P.T., Debaene, F., Cianferani, S., Reuter, K., Klebe, G., What glues a homodimer together: systematic analysis of the stabilizing effect of an aromatic hot spot in the protein–protein interface of the tRNA-modifying enzyme Tgt. ACS Chem. Biol. 10 (2015), 1897–1907.
32. [32] Snijder, J., Heck, A.J., Analytical approaches for size and mass analysis of large protein assemblies. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 7 (2014), 43–64.
33. [33] van Duijn, E., Barbu, I.M., Barendregt, A., Jore, M.M., Wiedenheft, B., Lundgren, M., Westra, E.R., Brouns, S.J., Doudna, J.A., van der Oost, J., Heck, A.J., Native tandem and ion mobility mass spectrometry highlight structural and modular similarities in clustered-regularly-interspaced shot-palindromic-repeats (CRISPR)-associated protein complexes from Escherichia coli and Pseudomonas aeruginosa. Mol. Cell. Proteomics 11 (2012), 1430–1441.
34. [34] Saliou, J.M., Manival, X., Tillault, A.S., Atmanene, C., Bobo, C., Branlant, C., Van Dorsselaer, A., Charpentier, B., Cianferani, S., Combining native MS approaches to decipher archaeal box H/ACA ribonucleoprotein particle structure and activity. Proteomics 15 (2015), 2851–2861.
35. [35] Martinez-Zapien, D., Saliou, J.M., Han, X., Atmanene, C., Proux, F., Cianferani, S., Dock-Bregeon, A.C., Intermolecular recognition of the non-coding RNA 7SK and HEXIM protein in perspective. Biochimie 117 (2015), 63–71.
36. [36] Bereszczak, J.Z., Barbu, I.M., Tan, M., Xia, M., Jiang, X., van Duijn, E., Heck, A.J., Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry. J. Struct. Biol. 177 (2012), 273–282.
37. [37] Bereszczak, J.Z., Havlik, M., Weiss, V.U., Marchetti-Deschmann, M., van Duijn, E., Watts, N.R., Wingfield, P.T., Allmaier, G., Steven, A.C., Heck, A.J., Sizing up large protein complexes by electrospray ionisation-based electrophoretic mobility and native mass spectrometry: morphology selective binding of Fabs to hepatitis B virus capsids. Anal. Bioanal. Chem. 406 (2014), 1437–1446.
38. [38] Snijder, J., Rose, R.J., Veesler, D., Johnson, J.E., Heck, A.J., Studying 18 MDa virus assemblies with native mass spectrometry. Angew. Chem. Int. Ed. Engl. 52 (2013), 4020–4023.
39. [39] Zhang, H., Cui, W., Gross, M.L., Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies. FEBS Lett. 588 (2014), 308–317.
40. [40] Thompson, N.J., Rosati, S., Heck, A.J., Performing native mass spectrometry analysis on therapeutic antibodies. Methods 65 (2014), 11–17.
41. [41] Rosati, S., Yang, Y., Barendregt, A., Heck, A.J., Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat. Protoc. 9 (2014), 967–976.
42. [42] Atmanene, C., Wagner-Rousset, E., Corvaia, N., Van Dorsselaer, A., Beck, A., Sanglier-Cianferani, S., Noncovalent mass spectrometry for the characterization of antibody/antigen complexes. Methods Mol. Biol. 988 (2013), 243–268.
43. [43] Fornelli, L., Damoc, E., Thomas, P.M., Kelleher, N.L., Aizikov, K., Denisov, E., Makarov, A., Tsybin, Y.O., Analysis of intact monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS. Mol. Cell. Proteomics 11 (2012), 1758–1767.
44. [44] Fornelli, L., Ayoub, D., Aizikov, K., Beck, A., Tsybin, Y.O., Middle-down analysis of monoclonal antibodies with electron transfer dissociation Orbitrap fourier transform mass spectrometry. Anal. Chem. 86 (2014), 3005–3012.
45. [45] Rose, R.J., Damoc, E., Denisov, E., Makarov, A., Heck, A.J., High-sensitivity Orbitrap mass analysis of intact macromolecular assemblies. Nat. Methods 9 (2012), 1084–1086.
46. [46] Labrijn, A.F., Buijsse, A.O., van den Bremer, E.T., Verwilligen, A.Y., Bleeker, W.K., Thorpe, S.J., Killestein, J., Polman, C.H., Aalberse, R.C., Schuurman, J., van de Winkel, J.G., Parren, P.W., Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27 (2009), 767–771.
47. [47] Rose, R.J., Labrijn, A.F., van den Bremer, E.T., Loverix, S., Lasters, I., van Berkel, P.H., van de Winkel, J.G., Schuurman, J., Parren, P.W., Heck, A.J., Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 19 (2011), 1274–1282.
48. [48] Debaene, F., Wagner-Rousset, E., Colas, O., Ayoub, D., Corvaia, N., Van Dorsselaer, A., Beck, A., Cianferani, S., Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and bispecific monoclonal antibody formation. Anal. Chem. 85 (2013), 9785–9792.
49. [49] Wakankar, A., Chen, Y., Gokarn, Y., Jacobson, F.S., Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3 (2011), 161–172.
50. [50] Valliere-Douglass, J.F., McFee, W.A., Salas-Solano, O., Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal. Chem. 84 (2012), 2843–2849.
51. [51] Hengel, S.M., Sanderson, R., Valliere-Douglass, J., Nicholas, N., Leiske, C., Alley, S.C., Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal. Chem. 86 (2014), 3420–3425.
52. [52] Chen, J., Yin, S., Wu, Y., Ouyang, J., Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal. Chem. 85 (2013), 1699–1704.
53. [53] Rosati, S., van den Bremer, E.T., Schuurman, J., Parren, P.W., Kamerling, J.P., Heck, A.J., In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs 5 (2013), 917–924.
54. [54] Debaene, F., Boeuf, A., Wagner-Rousset, E., Colas, O., Ayoub, D., Corvaia, N., Van Dorsselaer, A., Beck, A., Cianferani, S., Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal. Chem. 86 (2014), 10674–10683.
55. [55] Marcoux, J., Champion, T., Colas, O., Wagner-Rousset, E., Corvaia, N., Van Dorsselaer, A., Beck, A., Cianferani, S., Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci. 24 (2015), 1210–1223.
56. [56] Guo, J., Kumar, S., Prashad, A., Starkey, J., Singh, S.K., Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol-maleimide chemistry. Pharm. Res. 31 (2014), 1710–1723.
57. [57] Kukrer, B., Filipe, V., van Duijn, E., Kasper, P.T., Vreeken, R.J., Heck, A.J., Jiskoot, W., Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm. Res. 27 (2010), 2197–2204.
58. [58] Haberger, M., Heidenreich, A.K., Schlothauer, T., Hook, M., Gassner, J., Bomans, K., Yegres, M., Zwick, A., Zimmermann, B., Wegele, H., Bonnington, L., Reusch, D., Bulau, P., Functional assessment of antibody oxidation by native mass spectrometry. MAbs 7 (2015), 891–900.
59. [59] Haberger, M., Leiss, M., Heidenreich, A.K., Pester, O., Hafenmair, G., Hook, M., Bonnington, L., Wegele, H., Haindl, M., Reusch, D., Bulau, P., Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry. MAbs, 0, 2015.
60. [60] Rehder, D.S., Chelius, D., McAuley, A., Dillon, T.M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D.N., Matsumura, M., Bondarenko, P.V., Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin γ2 antibody highlights the role avidity plays in antibody activity. Biochemistry-Us 47 (2008), 2518–2530.
61. [61] Atmanene, C., Wagner-Rousset, E., Malissard, M., Chol, B., Robert, A., Corvaia, N., Van Dorsselaer, A., Beck, A., Sanglier-Cianferani, S., Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS. Anal. Chem. 81 (2009), 6364–6373.
62. [62] Pritchard, C., Groves, K.J., Biesenbruch, S., O'Connor, G., Ashcroft, A.E., Arsene, C., Schulze, D., Quaglia, M., Quantification of human growth hormone in serum with a labeled protein as an internal standard: essential considerations. Anal. Chem. 86 (2014), 6525–6532.
63. [63] Rosati, S., Rose, R.J., Thompson, N.J., van Duijn, E., Damoc, E., Denisov, E., Makarov, A., Heck, A.J., Exploring an orbitrap analyzer for the characterization of intact antibodies by native mass spectrometry. Angew. Chem. Int. Ed. Engl. 51 (2012), 12992–12996.
64. [64] Dyachenko, A., Wang, G., Belov, M., Makarov, A., de Jong, R.N., van den Bremer, E.T., Parren, P.W., Heck, A.J., Tandem native mass-spectrometry on antibody-drug conjugates and submillion da antibody-antigen protein assemblies on an Orbitrap EMR equipped with a high-mass quadrupole mass selector. Anal. Chem. 87 (2015), 6095–6102.
65. [65] Tito, M.A., Miller, J., Walker, N., Griffin, K.F., Williamson, E.D., Despeyroux-Hill, D., Titball, R.W., Robinson, C.V., Probing molecular interactions in intact antibody: antigen complexes an electrospray time-of-flight mass spectrometry approach. Biophys. J. 81 (2001), 3503–3509.
66. [66] Arthur, K.K., Gabrielson, J.P., Hawkins, N., Anafi, D., Wypych, J., Nagi, A., Sullivan, J.K., Bondarenko, P.V., In vitro stoichiometry of complexes between the soluble RANK ligand and the monoclonal antibody denosumab. Biochemistry-Us 51 (2012), 795–806.
67. [67] Oda, M., Uchiyama, S., Noda, M., Nishi, Y., Koga, M., Mayanagi, K., Robinson, C.V., Fukui, K., Kobayashi, Y., Morikawa, K., Azuma, T., Effects of antibody affinity and antigen valence on molecular forms of immune complexes. Mol. Immunol. 47 (2009), 357–364.
68. [68] Oda, M., Uchiyama, S., Robinson, C.V., Fukui, K., Kobayashi, Y., Azuma, T., Regional and segmental flexibility of antibodies in interaction with antigens of different size. FEBS J. 273 (2006), 1476–1487.
69. [69] Thompson, N.J., Hendriks, L.J., de Kruif, J., Throsby, M., Heck, A.J., Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry. MAbs 6 (2014), 197–203.
70. [70] Hall, Z., Politis, A., Bush, M.F., Smith, L.J., Robinson, C.V., Charge-state dependent compaction and dissociation of protein complexes: insights from ion mobility and molecular dynamics. J. Am. Chem. Soc. 134 (2012), 3429–3438.
71. [71] Mehmood, S., Marcoux, J., Hopper, J.T., Allison, T.M., Liko, I., Borysik, A.J., Robinson, C.V., Charge reduction stabilizes intact membrane protein complexes for mass spectrometry. J. Am. Chem. Soc. 136 (2014), 17010–17012.
72. [72] Pacholarz, K.J., Barran, P.E., Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry. Eupa Open Proteomics 11 (2016), 23–27.
73. [73] Gautier, V., Boumeester, A.J., Lossl, P., Heck, A.J., Lysine conjugation properties in human IgGs studied by integrating high-resolution native mass spectrometry and bottom-up proteomics. Proteomics 15 (2015), 2756–2765.
74. [74] Belov, M.E., Damoc, E., Denisov, E., Compton, P.D., Horning, S., Makarov, A.A., Kelleher, N.L., From protein complexes to subunit backbone fragments: a multi-stage approach to native mass spectrometry. Anal. Chem. 85 (2013), 11163–11173.
75. [75] Ruotolo, B.T., Giles, K., Campuzano, I., Sandercock, A.M., Bateman, R.H., Robinson, C.V., Evidence for macromolecular protein rings in the absence of bulk water. Science 310 (2005), 1658–1661.
76. [76] Uetrecht, C., Rose, R.J., van Duijn, E., Lorenzen, K., Heck, A.J., Ion mobility mass spectrometry of proteins and protein assemblies. Chem. Soc. Rev. 39 (2010), 1633–1655.
77. [77] Scarff, C.A., Patel, V.J., Thalassinos, K., Scrivens, J.H., Probing hemoglobin structure by means of traveling-wave ion mobility mass spectrometry. J. Am. Soc. Mass Spectrom. 20 (2009), 625–631.
78. [78] Bagal, D., Valliere-Douglass, J.F., Balland, A., Schnier, P.D., Resolving disulfide structural isoforms of IgG2 monoclonal antibodies by ion mobility mass spectrometry. Anal. Chem. 82 (2010), 6751–6755.
79. [79] Bowers, M.T., Kemper, P.R., von Helden, G., van Koppen, P.A., Gas-phase ion chromatography: transition metal state selection and carbon cluster formation. Science 260 (1993), 1446–1451.
80. [80] Barrera, N.P., Di Bartolo, N., Booth, P.J., Robinson, C.V., Micelles protect membrane complexes from solution to vacuum. Science 321 (2008), 243–246.
81. [81] Marcoux, J., Politis, A., Rinehart, D., Marshall, D.P., Wallace, M.I., Tamm, L.K., Robinson, C.V., Mass spectrometry defines the C-terminal dimerization domain and enables modeling of the structure of full-length OmpA. Structure 22 (2014), 781–790.
82. [82] Olivova, P., Chen, W.B., Chakraborty, A.B., Gebler, J.C., Determination of N-glycosylation sites and site heterogeneity in a monoclonal antibody by electrospray quadrupole ion-mobility time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 22 (2008), 29–40.
83. [83] Damen, C.W., Chen, W., Chakraborty, A.B., van Oosterhout, M., Mazzeo, J.R., Gebler, J.C., Schellens, J.H., Rosing, H., Beijnen, J.H., Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J. Am. Soc. Mass Spectrom. 20 (2009), 2021–2033.
84. [84] Jones, L.M., Zhang, H., Cui, W., Kumar, S., Sperry, J.B., Carroll, J.A., Gross, M.L., Complementary MS methods assist conformational characterization of antibodies with altered S–S bonding networks. J. Am. Soc. Mass Spectrom. 24 (2013), 835–845.
85. [85] Pacholarz, K.J., Porrini, M., Garlish, R.A., Burnley, R.J., Taylor, R.J., Henry, A.J., Barran, P.E., Dynamics of intact immunoglobulin G explored by drift-tube ion-mobility mass spectrometry and molecular modeling. Angew. Chem. Int. Ed. Engl. 53 (2014), 7765–7769.
86. [86] Tian, Y., Han, L., Buckner, A.C., Ruotolo, B.T., Collision induced unfolding of intact antibodies: rapid characterization of disulfide bonding patterns, glycosylation, and structures. Anal. Chem. 87 (2015), 11509–11515.
87. [87] Pacholarz, K., Peters, S.J., Garlish, R.A., Henry, A.J., Taylor, R.J., Humphreys, D.P., Barran, P.E., Molecular insights to the thermal stability of mAbs with variable temperature ion mobility mass spectrometry. ChemBioChem, 2015.
88. [88] Hyung, S.J., Robinson, C.V., Ruotolo, B.T., Gas-phase unfolding and disassembly reveals stability differences in ligand-bound multiprotein complexes. Chem. Biol. 16 (2009), 382–390.
89. [89] Li, X., Patterson, J.T., Sarkar, M., Pedzisa, L., Kodadek, T., Roush, W.R., Rader, C., Site-specific dual antibody conjugation via engineered cysteine and selenocysteine residues. Bioconjug. Chem. 26 (2015), 2243–2248.
90. [90] Merten, H., Brandl, F., Pluckthun, A., Zangemeister-Wittke, U., Antibody-drug conjugates for tumor targeting-novel conjugation chemistries and the promise of non-IgG binding proteins. Bioconjug. Chem. 26 (2015), 2176–2185.